With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...

Patients with neuropathic bladder (NB), a condition in which nerve damage affects bladder function, have a significantly ...

Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...

A new study suggests a common eye condition could be quietly masking one of the only early warning signs of bladder cancer — the 10th leading cause of cancer deaths in the US. Researchers found people ...

Discover how urinary microRNA biomarkers can non-invasively identify aggressive bladder cancer subtypes. Read more on this ...

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing Phase 2 ADVANCED-2 trial. ADVANCED-2 ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License ...